

The background is a solid teal color with several large, overlapping, 3D-style geometric shapes in a slightly darker shade of teal. These shapes create a sense of depth and movement, resembling architectural elements or abstract patterns. The shapes are primarily angular, with some curved lines, and they are arranged in a way that suggests a dynamic, forward-moving structure.

Adelphi

# A career in Medical Communications

Transforming **complex science** into engaging  
easy-to-digest **communications**

Christine Smart, Adelphi Communications Ltd

# Which path will you take?

**Do you love science, and  
want a career where you  
can apply your scientific  
knowledge and skills?**



# What is Medical Communications (MedComms)?


- Working with pharma and biotech clients
- Graduate jobs within MedComms
- MedComms: What do we actually do?
- What qualities are we looking for in candidates?
- Applying for a job in MedComms
- Summary



# What is Medical Communications (MedComms)?

- We ensure that healthcare professionals have the **right education** in the **right place** at the **right time**...
- ...to **transform patient outcomes** for the better
- In MedComms, we are passionate about explaining science at the right level for the right audience





Medical Communications | The Adelphi Way

# MedComms: Diverse therapy areas


# MedComms: Client teams we work with

- Medical Affairs
  - Clinical development
  - Clinical pharmacology
  - Preclinical research
  - HEOR
  - Patient-reported outcomes
  - Marketing
  - PR
  - Corporate Communications Teams
  - Regulatory
  - Patient Communications/Patient Affairs
  - Statisticians
  - Legal
- International experts
    - Clinical doctors
    - Nurses
    - Radiologists
    - Epidemiologists



# Graduate jobs within medical communications

- Associate Medical Writer
- Client Services Executive
- Associate Editorial Assistant
- Database Coordinator



Medical Communications | The Adelphi Way

# MedComms: What do we actually do?

Publication planning and delivery

**The NEW ENGLAND JOURNAL of MEDICINE**

ORIGINAL ARTICLE

**Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension**

Hossein-Ardeschir Ghofrani, M.D., Andrea M. D'Armini, M.D., Friedrich Grimminger, M.D., Marius M. Hooper, M.D., Pavel Jansa, M.D., Nick H. Kim, M.D., Eckhard Mayer, M.D., Gerald Simonneau, M.D., Martin R. Wilkins, M.D., Arno Fritsch, Ph.D., Dieter Neuser, M.D., Gerrit Weimann, M.D., and Chen Wang, M.D., for the CHEST-1 Study Group

**ABSTRACT**

**BACKGROUND**  
Riociguat, a member of a new class of compounds (soluble guanylate cyclase s-talors), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension.

**METHODS**  
In this phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat. The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 minutes. Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clinical worsening, Borg dyspnea score, quality-of-life variables, and safety.




we were also able to show that patients who had higher levels

- Conjunctivitis associated factors
- More severe atopic dermatitis
  - Prior history of conjunctivitis
  - Biomarkers: TARC (CCL17), IgE, blood eosinophils


Improves symptoms in patients with... is a type of antibody and may... system. When work less well, and... is some evidence... drugs are more likely given on their own... combination with... drugs. Our study... une attack on... on its own, and

whether this affected how well worked, and whether it produced unwanted side effects. We studied 132 patients with



of a mean of 30 m... in the placebo... (CI, 25 to 67; P<0.001),... cm\* in the riociguat... group (least-squares mean... 1001). Riociguat was also... BNP level (P<0.001) and... less adverse events were... and syncope (in 2% of the

monary vascular resistance... tension. (Funded by Bayer... bers, NCT00855465 and




**NO NEW SAFETY SIGNALS**

Sarilumab safety profile remained stable over 5 years and consistent with IL-6 blockade. Most common AEs (with any dose of sarilumab) were injection-site erythema, neutropenia, and upper respiratory tract infection (incidence rates of 13.5, 12.6, and 7.6 per 100 patient-years, respectively).

The Journal of Rheumatology

681 followers

View the video abstract by Dr. Laure Gossec on behalf of her co-authors, for their article Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale, published in our Octo...see more



**INHIBITION OF RADIOGRAPHIC PROGRESSION**

**Visual Abstract**

**Immobilising ankle fractures**

How long should casts or orthoses be used to restrict movement after a break?

**Summary**  
A shorter 3-week period of immobilisation proved non-inferior to traditional 6 weeks of cast immobilisation.

**Population**  
Scientific mature patients with an isolated, stable Weber B type fibula fracture

**Comparison**  
3 week orthosis vs 6 week cast vs 3 week cast

**Outcomes**

Outcome	3 week orthosis	6 week cast	3 week cast
Ankle function at 6 weeks	53	40	60
Ankle function at 12 weeks	70	55	69
Ankle function at 52 weeks	90	87	88

**Primary outcome**  
Ankle function (Olerud-Molander Ankle Score)

**Clinical significance**  
Pooled non-inferiority margin: 8.8 points



# MedComms: What do we actually do?

Advisory Boards and  
Medical Education



Patients with a PSADT ≤ 10 months are at significant risk of metastases or death

PSADT (months)	Relative risk for time to metastases or death
20	1.0
15	1.0
10	1.0
5	1.0
4	1.0
3	1.0
2	1.0
1	1.0
0	1.0

Enzalutamide median 20 months  
CRPC median 10 months

Chapters

- How should we select patients based on PSA parameters and/or imaging?
- PSADT in relation to MO CRPC therapy decisions
- How should we select patients based on imaging?
- What is the impact of long-term ADT on bone health and how we can avoid it?


Chat

Participant: Welcome to this live and interactive roundtable on the treatment of CRPC. If you have any questions for the faculty, please submit them via the chat-box on your screen, and they will be answered by the panel during the panel discussions.


Moderator 17:02: You can answer the poll by clicking on the answer on your screen

# MedComms: What do we actually do?

Internal training for client  
medical teams



Case discussions on specialist care in adult SMA



## What qualities are we looking for in medical writer candidates?

- Ability to understand complex data and explain it clearly to the target audience
- Clear and succinct writing style
- Excellent attention to detail
- Team player – ability to work closely with other writers, Client Services team, Database Coordinator, Editorial Assistants, Creative, Digital and Engagement team
- Good time management
- **What makes an Associate Medical Writer application stand out?**



# What qualities are we looking for in client services candidates?


- Highly organised and proactive
- Great attention to detail
- Ability to problem-solve and make decisions
- Excellent communication skills
- High level of drive, self-motivation and initiative
- Ability to work on multiple projects simultaneously
- Great team player, yet can also work autonomously in a fast-paced environment
- Commercial awareness
- Client-focused



# Applying for a job in MedComms



For Adelphi Communications, contact our Recruitment Coordinator  
[jobs@adelphigroup.com](mailto:jobs@adelphigroup.com)



# Applying for a job in MedComms

medcommsnetworking.com

firstmedcommsjob.com

September 2022

Ensuring timely dissemination of research

A guide to *working as a medical publications professional*

Written by Dr John P Gonzalez

For more information about careers in MedComms see [www.FirstMedCommsJob.com](http://www.FirstMedCommsJob.com)

March 2022

From academic to medical writer

A guide to *getting started in medical communications*

Written by Dr Annick Moon

For more information about careers in MedComms see [www.FirstMedCommsJob.com](http://www.FirstMedCommsJob.com)

January 2022

The business of medical communications

A guide to *getting started in account management*

Written by Lindsey Heer

For more information about careers in MedComms see [www.FirstMedCommsJob.com](http://www.FirstMedCommsJob.com)



## MedComms: What our teams say...

“

I enjoy working  
in a fast-paced  
environment  
where no two days  
are ever the same!



“

My job allows me to  
combine my passions  
for science and writing  
in a creative way

“

I love the varied  
nature of working  
in MedComms

# MedComms: Key take-homes

- Do you want to work in science, yet moving away from the lab?
- In MedComms, we are passionate about explaining science at the right level for the right audience – we ensure that healthcare professionals have the right education in the right place at the right time...
- MedComms – a career that really can make a difference to patient outcomes





Adelphi

**Any questions?**